Fig. 6

PLA2G16 is crucial for lncROPM-driven BCSCs formation. A, B qRT-PCR analysis of PLA2G16 expressions in non-BCSCs and BCSCs from various breast cancer cells (A) and clinical breast cancer samples (n = 30) (B). C Western blotting to determine PLA2G16 protein levels in non-BCSCs and BCSCs from BT549, MCF7, and clinical sample#5 cells. D, F Representative mammosphere images (D) and mammosphere-formation efficiencies (F) of BCSCs transfected with shPLA2G16-1, shPLA2G16-2 or treated with Giripladib (300 nM) for per generation, and their controls. E, G Representative mammosphere images (E) and mammosphere-formation efficiencies (G) of non-BCSCs transfected with LEV and LV-PLA2G16 lentivirus. n.d. not detected. H Ectopic PLA2G16 or control vector was transfected into lncROPM-silenced BCSCs; mammosphere formation abilities were evaluated by suspending culture. The representative mammosphere images (upper panel) and mammosphere-formation efficiencies (down panel) are shown. I Mammosphere formation abilities of non-BCSCs with ectopic lncROPM were assessed by suspending culture. And representative mammosphere images (upper panel) and mammosphere-formation efficiencies (down panel) are shown. n.d. not detected. Images were taken at the magnification of × 100 and scale bar was 200 µm. Data are presented as the mean ± SD; *p < 0.05, **p < 0.01